| A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity. | |
| Gong, Jifang; Liu, Tianshu; Fan, Qingxia; Bai, Li; Bi, Feng; Qin, Shukui; Wang, Jinwan; Xu, Nong; Cheng, Ying; Bai, Yuxian | |
| 2014 | |
| 会议名称 | JOURNAL OF CLINICAL ONCOLOGY |
| 会议日期 | 2014-01-20 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6667253 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Gong, Jifang,Liu, Tianshu,Fan, Qingxia,et al. A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2014-01-20. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论